Harvard Bioscience (HBIO) Price to Sales (2010 - 2026)

Harvard Bioscience (HBIO) has reported Price to Sales for 17 consecutive years, with 1.23 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales rose 28.57% year-over-year to 1.23 in Q2 2026; TTM through Jun 2026 was 0.32, a 44.42% increase from a year earlier, with the FY2025 full-year figure at 0.35, down 64.96% from the prior year.
• Price to Sales was 1.23 for Q2 2026 at Harvard Bioscience, up from 1.06 in the prior quarter.
• Over five years, Price to Sales peaked at 8.9 in Q1 2022 and troughed at 0.95 in Q3 2025.
• A 5-year average of 4.46 and a median of 4.61 in 2022 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales surged 101.1% in 2023 and slumped 84.59% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 4.1 in 2022, then surged by 101.1% to 8.25 in 2023, then plunged by 54.08% to 3.79 in 2024, then plunged by 66.67% to 1.26 in 2025, then fell by 2.42% to 1.23 in 2026.
• The last three Price to Sales figures came in at 1.23 (Q2 2026), 1.06 (Q1 2026), and 1.26 (Q4 2025), per Business Quant data.